A first-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP
Phase 1
Recruiting
- Conditions
- Prophylactic vaccination against HPV in healthy volunteersTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- CTIS2024-511493-67-00
- Lead Sponsor
- Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method